PerpEquities

Equity · Healthcare

Summit Therapeutics Inc. (SMMT) perpetual futures

SMMT perpetual futures on 1 crypto exchanges – live perp price vs the stock, funding rate, open interest and where to trade SMMTUSDT.

Summit Therapeutics Inc. is a biopharmaceutical firm developing treatments for infectious diseases, focusing on Clostridioides difficile infection and multidrug-resistant bacteria.

$16.75+0.4%NASDAQ closed
Open in terminal

Price chart

 

Use the left and right arrow keys to inspect points on the chart.

Collecting venue price data...
venue perp mark · BingX (SMMT-USDT)
Auto: highest-volume live perp venueOpen in TradingView

Trading data

Perpetual market activity

1/1 live markets
Venues
1
Live markets
1/1
24h volume
-Coverage: 0/1 marketsExchange-reported volume: $1.2M
Open interest
$1.5K
Best liquidity
$18.8K
BingX
Tightest spread
+47.7 bps
BingX
Highest volume
-
Settlement mix
USDT · 1/1
Perp/spot vol.
-
Spot volume $86.9M
OI / float
0.00%
Float $1.8B
Spot performance
1D+0.39%
5D+8.10%
1M-4.86%
6M-10.35%
YTD-4.20%
1Y-24.36%

Venue matrix

1 markets

Some venue links are sponsored. We may receive a commission, and eligible users may occasionally receive trading-fee discounts, at no additional cost to you.

Trade
BingXTradeSMMT-USDTTrading$16.75-4.4% APR
-0.00400% every 8h
+47.7 bps$18.8K$1.2M⚠$1.5KUSDT-

Unverified volume: implausibly high against open interest, a typical sign of wash trading. These venues are listed last.

Tradability

Execution quality

Entry cost and depth per venue at $1k–$100k

Thin liquidity · 1 of 1 venues absorb $10k · Typical cost: +77.7 bps

Cheapest execution: BingX · +77.7 bps

Taker execution estimate incl. approx. fees - maker fills are not guaranteed.

Best venues for this underlying

Best liquidity

SMMT

Tightest spread

SMMT

Highest volume

-
No live data-

Funding history

Stored venue snapshots by market

Company data

Company fundamentals

Updated 38m ago
Market cap
$13.4B
Updated 38m ago
Revenue
$0
Trailing 12 months
Revenue growth
+1,706%
Next fiscal year
Profit margin
0.0%
P/E
-15.0
Peer P/E 22.2
Free cash flow
-$406.7M
Trailing 12 months
More metrics
Net income
-$856.1M
Trailing 12 months
P/S
-
Peer P/E
22.2
Similar listed perps
Revenue estimate
$3.7M
Next fiscal year
Earnings
2026-10-19
Revenue est. $71.4K · Updated 38m ago
Dividend
-

Fundamental detail

Annual + quarterly
Latest revenue$0
Net margin0.0%
Free cash flow-$240.2M
Net debt-$151.7M
2020$628.9K
2021$1.3M
2022$583.2K
2023$0
2024$0
2025$0
PeriodRevenueGrowthNet incomeFCF
2020$628.9K-22%-$38.5M-$35.6M
2021$1.3M+113%-$65.5M-$54M
2022$583.2K-56%-$65.2M-$34.4M
2023$0-100%-$482.4M-$60.8M
2024$0--$176.8M-$113.7M
2025$0--$1.1B-$240.2M
PeriodGross marginOperating marginNet marginROEROA
2020+100.0%-11,392.7%-6,127.6%-66.0%-51.2%
2021+100.0%-4,764.3%-4,897.8%-106.1%-78.0%
2022+100.0%-10,225.4%-11,174.8%-63.1%-12.0%
20230.0%0.0%0.0%-784.6%-300.3%
20240.0%0.0%0.0%-56.9%-50.8%
20250.0%0.0%0.0%-220.8%-193.6%
PeriodCashDebtNet debtCurrent ratio
2020$48.8M$341.5K-$48.4M4.41
2021$53.2M$2.1M-$51.2M3.80
2022$284.2M$422.9M$138.7M16.93
2023$56.5M$84M$27.4M9.30
2024$83.8M$5.8M-$78M10.15
2025$167.2M$15.5M-$151.7M9.87
PeriodMarket capEnterprise valueP/SP/E
2020$325.9M$277.4M518.2-8.5
2021$248.1M$197M185.5-3.8
2022$816.6M$955.4M1,400.3-12.5
2023$1.6B$1.6B0.0-3.3
2024$12.7B$12.7B0.0-71.4
2025$13.1B$12.9B0.0-12.1
Q3 2024$0
Q4 2024$0
Q1 2025$0
Q2 2025$0
Q3 2025$0
Q4 2025$0
Q1 2026$0
Q2 2026$0
PeriodRevenueGrowthNet incomeFCF
Q3 2024$0--$42.1M-$23.2M
Q4 2024$0--$48.9M-$38.9M
Q1 2025$0--$48.7M-$47.7M
Q2 2025$0--$412.2M-$49M
Q3 2025$0--$231.8M-$69.2M
Q4 2025$0--$219.2M-$75.8M
Q1 2026$0--$189.4M-$92.9M
Q2 2026$0--$215.7M-$168.7M
PeriodGross marginOperating marginNet marginROEROA
Q3 20240.0%0.0%0.0%-12.6%-11.0%
Q4 20240.0%0.0%0.0%-15.7%-14.0%
Q1 20250.0%0.0%0.0%-18.3%-16.4%
Q2 20250.0%0.0%0.0%-216.5%-173.3%
Q3 20250.0%0.0%0.0%-162.2%-119.1%
Q4 20250.0%0.0%0.0%-44.8%-39.3%
Q1 20260.0%0.0%0.0%-45.8%-38.6%
Q2 20260.0%0.0%0.0%-34.2%-28.7%
PeriodCashDebtNet debtCurrent ratio
Q3 2024$71.5M$24.8M-$46.7M8.31
Q4 2024$83.8M$5.8M-$78M10.15
Q1 2025$163.8M$5M-$158.8M10.63
Q2 2025$218.6M$4.1M-$214.5M5.13
Q3 2025$177.3M$4M-$173.3M3.80
Q4 2025$167.2M$15.5M-$151.7M9.87
Q1 2026$80.8M$15.2M-$65.6M7.41
Q2 2026$419.4M$20.4M-$399M6.96
PeriodMarket capEnterprise valueP/SP/E
Q3 2024$15.4B$15.4B0.0-94.6
Q4 2024$12.2B$12.1B0.0-67.3
Q1 2025$13.5B$13.3B0.0-73.1
Q2 2025$15.8B$15.6B0.0-9.5
Q3 2025$15.4B$15.2B0.0-16.7
Q4 2025$13.4B$13.3B0.0-15.1
Q1 2026$14.7B$14.6B0.0-19.8
Q2 2026$11.3B$10.9B0.0-13.0

Refreshed 38m ago

Charts: revenue, profit, cash flow & valuation
Revenue$0Q2 2026
Q3 2023: $0Q4 2023: $0Q1 2024: $0Q2 2024: $0Q3 2024: $0Q4 2024: $0Q1 2025: $0Q2 2025: $0Q3 2025: $0Q4 2025: $0Q1 2026: $0Q2 2026: $0Q3 2023Q2 2026
Net income-$215.7MQ2 2026
-$309.1M-$206.1M-$103MQ3 2023: -$17.4MQ4 2023: -$28.7MQ1 2024: -$34.5MQ2 2024: -$47.8MQ3 2024: -$42.1MQ4 2024: -$48.9MQ1 2025: -$48.7MQ2 2025: -$412.2MQ3 2025: -$231.8MQ4 2025: -$219.2MQ1 2026: -$189.4MQ2 2026: -$215.7MQ3 2023Q2 2026
EBITDA-$215.7MQ2 2026
-$310.6M-$207.1M-$103.5MQ3 2023: -$14.7MQ4 2023: -$25.8MQ1 2024: -$31.3MQ2 2024: -$35.3MQ3 2024: -$39.6MQ4 2024: -$48.9MQ1 2025: -$48.7MQ2 2025: -$414.1MQ3 2025: -$231.8MQ4 2025: -$219.1MQ1 2026: -$189.4MQ2 2026: -$215.7MQ3 2023Q2 2026
Free cash flow-$168.7MQ2 2026
-$126.6M-$84.4M-$42.2MQ3 2023: -$12.3MQ4 2023: -$15.4MQ1 2024: -$24MQ2 2024: -$26.1MQ3 2024: -$23.2MQ4 2024: -$38.9MQ1 2025: -$47.7MQ2 2025: -$49MQ3 2025: -$69.2MQ4 2025: -$75.8MQ1 2026: -$92.9MQ2 2026: -$168.7MQ3 2023Q2 2026
EPS-$0.28Q2 2026
-$0.42-$0.28-$0.14Q3 2023: -$0.03Q4 2023: -$0.04Q1 2024: -$0.05Q2 2024: -$0.07Q3 2024: -$0.06Q4 2024: -$0.07Q1 2025: -$0.07Q2 2025: -$0.56Q3 2025: -$0.31Q4 2025: -$0.29Q1 2026: -$0.24Q2 2026: -$0.28Q3 2023Q2 2026
Cash / Debt$419.4MQ2 2026
$104.8M$209.7M$314.5M$419.4MQ3 2023 · Cash: $19.6MQ3 2023 · Debt: $87.7MQ4 2023 · Cash: $56.5MQ4 2023 · Debt: $84MQ1 2024 · Cash: $48.8MQ1 2024 · Debt: $87.3MQ2 2024 · Cash: $22.5MQ2 2024 · Debt: $85.9MQ3 2024 · Cash: $71.5MQ3 2024 · Debt: $24.8MQ4 2024 · Cash: $83.8MQ4 2024 · Debt: $5.8MQ1 2025 · Cash: $163.8MQ1 2025 · Debt: $5MQ2 2025 · Cash: $218.6MQ2 2025 · Debt: $4.1MQ3 2025 · Cash: $177.3MQ3 2025 · Debt: $4MQ4 2025 · Cash: $167.2MQ4 2025 · Debt: $15.5MQ1 2026 · Cash: $80.8MQ1 2026 · Debt: $15.2MQ2 2026 · Cash: $419.4MQ2 2026 · Debt: $20.4MQ3 2023Q2 2026
CashDebt
Profitability0.0%Q2 2026
Q3 2023 · Gross margin: 0.0%Q4 2023 · Gross margin: 0.0%Q1 2024 · Gross margin: 0.0%Q2 2024 · Gross margin: 0.0%Q3 2024 · Gross margin: 0.0%Q4 2024 · Gross margin: 0.0%Q1 2025 · Gross margin: 0.0%Q2 2025 · Gross margin: 0.0%Q3 2025 · Gross margin: 0.0%Q4 2025 · Gross margin: 0.0%Q1 2026 · Gross margin: 0.0%Q2 2026 · Gross margin: 0.0%Q3 2023 · Operating margin: 0.0%Q4 2023 · Operating margin: 0.0%Q1 2024 · Operating margin: 0.0%Q2 2024 · Operating margin: 0.0%Q3 2024 · Operating margin: 0.0%Q4 2024 · Operating margin: 0.0%Q1 2025 · Operating margin: 0.0%Q2 2025 · Operating margin: 0.0%Q3 2025 · Operating margin: 0.0%Q4 2025 · Operating margin: 0.0%Q1 2026 · Operating margin: 0.0%Q2 2026 · Operating margin: 0.0%Q3 2023 · Net margin: 0.0%Q4 2023 · Net margin: 0.0%Q1 2024 · Net margin: 0.0%Q2 2024 · Net margin: 0.0%Q3 2024 · Net margin: 0.0%Q4 2024 · Net margin: 0.0%Q1 2025 · Net margin: 0.0%Q2 2025 · Net margin: 0.0%Q3 2025 · Net margin: 0.0%Q4 2025 · Net margin: 0.0%Q1 2026 · Net margin: 0.0%Q2 2026 · Net margin: 0.0%Q3 2023Q2 2026
Gross marginOperating marginNet margin
Shares outstanding778.2MQ2 2026
194.5M389.1M583.6M778.2MQ3 2023: 697.7MQ4 2023: 700.6MQ1 2024: 701.8MQ2 2024: 707.9MQ3 2024: 726.7MQ4 2024: 737.5MQ1 2025: 738.1MQ2 2025: 742.6MQ3 2025: 743.4MQ4 2025: 766.4MQ1 2026: 775.5MQ2 2026: 778.2MQ3 2023Q2 2026
Valuation-13.0Q2 2026
-70.9-47.3-23.6Q3 2023 · P/E: -18.7Q4 2023 · P/E: -16.0Q1 2024 · P/E: -20.3Q2 2024 · P/E: -30.1Q3 2024 · P/E: -94.6Q4 2024 · P/E: -67.3Q1 2025 · P/E: -73.1Q2 2025 · P/E: -9.5Q3 2025 · P/E: -16.7Q4 2025 · P/E: -15.1Q1 2026 · P/E: -19.8Q2 2026 · P/E: -13.0Q3 2023 · P/S: 0.0Q4 2023 · P/S: 0.0Q1 2024 · P/S: 0.0Q2 2024 · P/S: 0.0Q3 2024 · P/S: 0.0Q4 2024 · P/S: 0.0Q1 2025 · P/S: 0.0Q2 2025 · P/S: 0.0Q3 2025 · P/S: 0.0Q4 2025 · P/S: 0.0Q1 2026 · P/S: 0.0Q2 2026 · P/S: 0.0Q3 2023Q2 2026
P/EP/S
Revenue$02025
$18.9M$37.7M$56.6M$75.5M2018: $75.5M2019: $808.9K2020: $628.9K2021: $1.3M2022: $583.2K2023: $02024: $02025: $020182025
Net income-$1.1B2025
-$806.1M-$532.6M-$259.1M$14.4M2018: $14.4M2019: -$31.7M2020: -$38.5M2021: -$65.5M2022: -$65.2M2023: -$482.4M2024: -$176.8M2025: -$1.1B20182025
EBITDA-$1.1B2025
-$805.7M-$532M-$258.3M$15.4M2018: $15.4M2019: -$28.5M2020: -$37.1M2021: -$64.3M2022: -$51.6M2023: -$69.5M2024: -$168.5M2025: -$1.1B20182025
Free cash flow-$240.2M2025
-$180.1M-$120.1M-$60M2018: -$46.6M2019: -$20.9M2020: -$35.6M2021: -$54M2022: -$34.4M2023: -$60.8M2024: -$113.7M2025: -$240.2M20182025
EPS-$1.442025
-$1.04-$0.65-$0.25$0.152018: $0.152019: -$0.972020: -$0.562021: -$0.712022: -$0.342023: -$0.782024: -$0.252025: -$1.4420182025
Cash / Debt$167.2M2025
$105.7M$211.4M$317.2M$422.9M2018 · Cash: $46.6M2018 · Debt: $02019 · Cash: $66.1M2019 · Debt: $924.9K2020 · Cash: $48.8M2020 · Debt: $341.5K2021 · Cash: $53.2M2021 · Debt: $2.1M2022 · Cash: $284.2M2022 · Debt: $422.9M2023 · Cash: $56.5M2023 · Debt: $84M2024 · Cash: $83.8M2024 · Debt: $5.8M2025 · Cash: $167.2M2025 · Debt: $15.5M20182025
CashDebt
Profitability0.0%2025
-8,519.5%-5,646.4%-2,773.2%+100.0%2018 · Gross margin: +98.8%2019 · Gross margin: +100.0%2020 · Gross margin: +100.0%2021 · Gross margin: +100.0%2022 · Gross margin: +100.0%2023 · Gross margin: 0.0%2024 · Gross margin: 0.0%2025 · Gross margin: 0.0%2018 · Operating margin: +9.4%2019 · Operating margin: -3,697.6%2020 · Operating margin: -11,392.7%2021 · Operating margin: -4,764.3%2022 · Operating margin: -10,225.4%2023 · Operating margin: 0.0%2024 · Operating margin: 0.0%2025 · Operating margin: 0.0%2018 · Net margin: +19.0%2019 · Net margin: -3,920.2%2020 · Net margin: -6,127.6%2021 · Net margin: -4,897.8%2022 · Net margin: -11,174.8%2023 · Net margin: 0.0%2024 · Net margin: 0.0%2025 · Net margin: 0.0%20182025
Gross marginOperating marginNet margin
Revenue growth-100.0%2023
-46.8%+6.4%+59.5%+112.7%2019: -98.9%2020: -22.3%2021: +112.7%2022: -56.4%2023: -100.0%20182025
Shares outstanding747.7M2025
186.9M373.9M560.8M747.7M2018: 86.1M2019: 32.8M2020: 69.5M2021: 92.2M2022: 193.3M2023: 619.6M2024: 718.5M2025: 747.7M20182025
Valuation-12.12025
296.5664.51,032.41,400.32018 · P/E: 9.22019 · P/E: -1.72020 · P/E: -8.52021 · P/E: -3.82022 · P/E: -12.52023 · P/E: -3.32024 · P/E: -71.42025 · P/E: -12.12018 · P/S: 1.52019 · P/S: 64.52020 · P/S: 518.22021 · P/S: 185.52022 · P/S: 1,400.32023 · P/S: 0.02024 · P/S: 0.02025 · P/S: 0.020182025
P/EP/S

Next catalyst

Catalysts

Earnings
2026-10-19
Revenue est. $71.4K · Updated 38m ago

No unusual perp activity right now.

Research data

Analysts, filings and peer context

Estimates

6
DateEPS estimateRevenue estimateGrowthAnalysts
FY 2026-1.17$3.7M-9
FY 2027-1.13$59.5M-8
FY 2028-0.69$581.4M-7
FY 20290.09$1.7B-2
FY 20301.57$3.8B-4
Q3 2026-0.29$71.4K-7

Company events

6
2026-10-19EarningsActual - / Estimate -0.28-
2026-07-23EarningsActual -0.28 / Estimate -0.27Miss
2026-04-30EarningsActual -0.24 / Estimate -0.33Beat
2026-02-23EarningsActual -0.29 / Estimate -0.1Miss
2025-10-20EarningsActual -0.31 / Estimate -0.18Miss
2025-08-11EarningsActual -0.76 / Estimate -0.09Miss

Peer comparison

Similar listed perps

FMP company data

Company intelligence

Updated: Sep 22, 2026, 03:47 PM UTC

Company profile

Sector
Healthcare
Industry
Biotechnology
Chief executive
Robert W. Duggan
Employees
265
IPO date
Mar 5, 2015
Country
US
Exchange
NASDAQ Global Market
Website
Altman Z-scorei42.39
Piotroski scorei2/9
FMP ratingiC
Owner earningsi-$167.78M-$0.22 per share
ESG risk ratingiBIndustry rank: 285 out of 724

Rating factors

Return on equityi
1
Return on assetsi
1
Debt to equityi
4
Price to earningsi
1
Price to booki
1
Market cap history
$13.15B+18.8%Jun 26 – Sep 26
$9.91B$12.12B$14.33BHigh: $14.33B · 2026-09-14Low: $9.91B · 2026-08-24Latest: $13.15B · 2026-09-21Jun 26Jul 26Aug 26Sep 26
Latest: $13.15B · 2026-09-21High: $14.33B · 2026-09-14Low: $9.91B · 2026-08-24
Largest fund holders
FundWeightShares held
XBI1.27%7.6M
VTI0%3.7M
VB0.02%2.7M
FDGRX0.04%2M
VXF0.03%1.8M
VBR0.03%1.7M
IBB0.17%1M
FBIOX0.24%803.5K
NIW0.06%773.3K
IWP0.07%769.7K
BTEC.L0.96%629.6K
FSPHX0.17%602.1K

Analyst track record

How the analysts covering SMMT have done: ratings, price-target accuracy and the measured reaction after their calls.

12 months3 years
Ratings115234
Analysts2227
Buy / hold / sell74 / 35 / 6182 / 38 / 14
Upgrades / downgrades / initiations3 / 2 / 24 / 3 / 19
Price targets hit / missed12 / 76 (14%)29 / 150 (16%)
Avg. return after a rating (TipRanks)-35.4%-34.2%
Best / worst call+70.3% / -87.4%+138.4% / -87.4%

After buy calls on this stock: median 21-day move +0.1% vs S&P 500 -1.9% (n = 170)

Most accurate on this stock

Share of an analyst's price targets on this stock that the price reached within 12 months (our measurement over the last 3 years, at least 8 targets). It describes past calls, not the odds of the current one.

  1. Bradley CaninoGuggenheim55% hit rate on this stock · 11 targets measuredBuytarget $38.00Jul 23, 2026
  2. Yigal NochomovitzCiti45% hit rate on this stock · 11 targets measuredBuytarget $43.00Sep 29, 2026
  3. Mitchell KapoorH.C. Wainwright17% hit rate on this stock · 23 targets measuredHoldno targetSep 29, 2026

Latest ratings

DateAnalystCallTarget
Oct 1, 2026Etzer DaroutBarclaysHoldMaintained$20.00
Sep 29, 2026Faisal KhurshidJefferiesBuyMaintained–
Sep 30, 2026Mitchell KapoorH.C. WainwrightHoldReiterated–
Sep 29, 2026Mitchell KapoorH.C. WainwrightHoldReiterated–
Sep 29, 2026Dara AzarStifel NicolausBuyMaintained–
Consensus over the last 12 months buy hold sell avg. target month-end close
Monthly buy, hold and sell shares of analyst ratings with the average price target and the month-end close$15.00$20.00$25.00$30.00$35.00$40.00Nov 25 · Buy 13 · Hold 2 · Sell 3Nov 25Dec 25 · Buy 13 · Hold 3 · Sell 2Jan 26 · Buy 11 · Hold 3 · Sell 2Jan 26Feb 26 · Buy 11 · Hold 3 · Sell 2Mar 26 · Buy 10 · Hold 4 · Sell 1Mar 26Apr 26 · Buy 11 · Hold 4 · Sell 0May 26 · Buy 9 · Hold 4 · Sell 0May 26Jun 26 · Buy 9 · Hold 4 · Sell 1Jul 26 · Buy 10 · Hold 4 · Sell 1Jul 26Aug 26 · Buy 10 · Hold 6 · Sell 0Sep 26 · Buy 12 · Hold 6 · Sell 0Sep 26Oct 26 · Buy 12 · Hold 6 · Sell 0Nov 25 · avg. target $30.82Dec 25 · avg. target $39.35Jan 26 · avg. target $39.35Feb 26 · avg. target $30.17Mar 26 · avg. target $29.45Apr 26 · avg. target $31.54May 26 · avg. target $31.55Jun 26 · avg. target $29.73Jul 26 · avg. target $28.98Aug 26 · avg. target $28.99Sep 26 · avg. target $28.53Oct 26 · avg. target $28.68Nov 25 · month-end close $17.89Dec 25 · month-end close $17.49Jan 26 · month-end close $14.48Feb 26 · month-end close $16.59Mar 26 · month-end close $18.96Apr 26 · month-end close $21.46May 26 · month-end close $17.54Jun 26 · month-end close $14.57Jul 26 · month-end close $13.02Aug 26 · month-end close $13.62Sep 26 · month-end close $16.91Oct 26 · month-end close $16.76

Share of analysts per call each month (latest call per analyst within 180 days). Targets and closes in USD.

TipRanks data via FMP · computed Oct 2, 2026 · 115 ratings

Frequently asked questions

Where can I trade SMMT perpetual futures?

Summit Therapeutics Inc. (SMMT) perpetual futures trade on 1 crypto venues, including BingX. PerpEquities compares them by live price, funding rate, open interest and liquidity.

Can I trade SMMT around the clock?

Yes. Unlike the underlying stock, SMMT perpetuals trade 24/7 — including weekends and outside regular market hours.

What is the funding rate on SMMT perpetuals?

Right now the SMMT perp funding rate is -4.4% annualized (venue median), ranging from -4.4% to -4.4% across 1 venues. A positive rate means longs pay shorts. PerpEquities shows the live rate and its history for every venue.

How does the SMMT perp price compare to the Summit Therapeutics Inc. stock?

The venue-median SMMT perp mark is $16.8 versus a reference stock price of $16.8, a basis of 0.0%. Perps follow the stock through an index price; the gap widens when funding or liquidity diverge between venues.

What is a SMMT perpetual future?

A SMMT perpetual is a derivative that tracks the price of Summit Therapeutics Inc. with no expiry date. It lets you take long or short exposure to Summit Therapeutics Inc. on crypto venues, around the clock.

What is SMMTUSDT perpetual?

SMMTUSDT is the symbol most crypto exchanges use for the Summit Therapeutics Inc. perpetual settled in USDT (Tether). It tracks the SMMT share price through an index, trades 24/7 with leverage and never expires.

Embed this asset

SMMT perpetuals · perpequities.comSMMT perpetuals · perpequities.com
<a href="https://perpequities.com/stocks/smmt-perp"><img src="https://perpequities.com/badge/smmt-perp.svg" width="240" height="64" alt="SMMT perpetuals · perpequities.com" loading="lazy"></a>

Next step

Stay on top of SMMT perps

Signals with a track record

Analysts who hit 70%+ of their targets on the perps we track, congress buys over $500k, 13F positions over $5M, funding spreads that have paid for days. Every post shows the evidence. Free, no sign-up.

Join on Telegram

Weekly digest by email

The listings, funding and moves that matter for SMMT — one email every Sunday.

Watchlist and alerts

Price and funding alerts for SMMT, via push or Telegram.

Set an alert

Follow the live feed

Daily movers, new listings and funding extremes as they happen.

Follow on X